Hirano Teruyuki
Department of Stroke and Cerebrovascular Medicine, Kyorin University Faculty of Medicine.
Brain Nerve. 2017 Jun;69(6):651-656. doi: 10.11477/mf.1416200796.
A new clinical construct, embolic stroke of undetermined source (ESUS) was established as a therapeutically relevant entity, which are defined as a non-lacunar infarction without proximal arterial stenosis or cardioembolic sources, with a clear indication for anticoagulation, especially with direct oral anticoagulant (DOAC). The possible embolic sources include covert atrial fibrillation, arterial stenosis with <50%, low-risk emboligenic cardiac sources, aortic plaque, cancer-associated, and paradoxical embolism. As its diagnosis is based on exclusive process, ESUS comprises heterogeneous pathologies. Though current Japanese guideline recommends antiplatelets for non-cardioembolic stroke, ESUS may benefits from anticoagulants. Randomized trials testing DOAC for the secondary prevention of ESUS are currently ongoing.
一种新的临床概念——不明来源栓塞性卒中(ESUS)被确立为一个具有治疗相关性的实体,其定义为非腔隙性梗死,无近端动脉狭窄或心源性栓塞来源,有明确的抗凝指征,尤其是使用直接口服抗凝剂(DOAC)。可能的栓塞来源包括隐匿性心房颤动、<50%的动脉狭窄、低风险致栓性心脏来源、主动脉斑块、癌症相关以及反常栓塞。由于其诊断基于排除过程,ESUS包含多种不同的病理情况。尽管目前日本指南推荐对非心源性栓塞性卒中使用抗血小板药物,但ESUS可能从抗凝治疗中获益。目前正在进行测试DOAC用于ESUS二级预防的随机试验。